BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26315382)

  • 1. TP53 dysfunction in diffuse large B-cell lymphoma.
    Lu TX; Young KH; Xu W; Li JY
    Crit Rev Oncol Hematol; 2016 Jan; 97():47-55. PubMed ID: 26315382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
    Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
    Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.
    Booman M; Szuhai K; Rosenwald A; Hartmann E; Kluin-Nelemans H; de Jong D; Schuuring E; Kluin P
    J Pathol; 2008 Oct; 216(2):209-17. PubMed ID: 18729069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
    Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
    Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular control of the cell cycle in cancer: biological and clinical aspects.
    Møller MB
    Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
    Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
    Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Bohers E; Mareschal S; Bertrand P; Viailly PJ; Dubois S; Maingonnat C; Ruminy P; Tilly H; Jardin F
    Leuk Lymphoma; 2015 May; 56(5):1213-22. PubMed ID: 25130477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation.
    Singh RR; Kim JE; Davuluri Y; Drakos E; Cho-Vega JH; Amin HM; Vega F
    Leukemia; 2010 May; 24(5):1025-36. PubMed ID: 20200556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
    Mareschal S; Dubois S; Viailly PJ; Bertrand P; Bohers E; Maingonnat C; Jaïs JP; Tesson B; Ruminy P; Peyrouze P; Copie-Bergman C; Fest T; Jo Molina T; Haioun C; Salles G; Tilly H; Lecroq T; Leroy K; Jardin F
    Genes Chromosomes Cancer; 2016 Mar; 55(3):251-67. PubMed ID: 26608593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy.
    Troppan K; Wenzl K; Deutsch A; Ling H; Neumeister P; Pichler M
    Anticancer Res; 2014 Feb; 34(2):557-64. PubMed ID: 24510984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL).
    Mazan-Mamczarz K; Gartenhaus RB
    Leuk Res; 2013 Nov; 37(11):1420-8. PubMed ID: 24054860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.
    Scandurra M; Rossi D; Deambrogi C; Rancoita PM; Chigrinova E; Mian M; Cerri M; Rasi S; Sozzi E; Forconi F; Ponzoni M; Moreno SM; Piris MA; Inghirami G; Zucca E; Gattei V; Rinaldi A; Kwee I; Gaidano G; Bertoni F
    Hematol Oncol; 2010 Jun; 28(2):62-7. PubMed ID: 20014148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.
    Jardin F
    Discov Med; 2014; 18(97):51-65. PubMed ID: 25091488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
    Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
    Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.
    Monti S; Chapuy B; Takeyama K; Rodig SJ; Hao Y; Yeda KT; Inguilizian H; Mermel C; Currie T; Dogan A; Kutok JL; Beroukhim R; Neuberg D; Habermann TM; Getz G; Kung AL; Golub TR; Shipp MA
    Cancer Cell; 2012 Sep; 22(3):359-72. PubMed ID: 22975378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas.
    Jardin F; Ruminy P; Kerckaert JP; Parmentier F; Picquenot JM; Quief S; Villenet C; Buchonnet G; Tosi M; Frebourg T; Bastard C; Tilly H
    Haematologica; 2008 Apr; 93(4):543-50. PubMed ID: 18287131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.
    Rinaldi A; Mensah AA; Kwee I; Forconi F; Orlandi EM; Lucioni M; Gattei V; Marasca R; Berger F; Cogliatti S; Cavalli F; Zucca E; Gaidano G; Rossi D; Bertoni F
    Br J Haematol; 2013 Oct; 163(2):194-204. PubMed ID: 23961875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes.
    Amara K; Trimeche M; Ziadi S; Laatiri A; Hachana M; Sriha B; Mokni M; Korbi S
    Int J Cancer; 2007 Dec; 121(12):2693-702. PubMed ID: 17724719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
    Young KH; Weisenburger DD; Dave BJ; Smith L; Sanger W; Iqbal J; Campo E; Delabie J; Gascoyne RD; Ott G; Rimsza L; Müller-Hermelink HK; Jaffe ES; Rosenwald A; Staudt LM; Chan WC; Greiner TC
    Blood; 2007 Dec; 110(13):4396-405. PubMed ID: 17881637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.